文献速递淋巴瘤

BrECADD方案治疗晚期经典型霍奇金淋巴瘤的真实世界多中心回顾性研究

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.
PubMed 文献 · Br J Haematol · 2026-07-14

该多中心回顾性研究纳入19个癌症中心2023年7月至2025年10月接受BrECADD治疗的100例晚期经典型霍奇金淋巴瘤患者,中位年龄30岁,80%为IV期,85%国际预后评分≥3。中位随访13.7个月,1年无进展生存率和总生存率分别为96%和100%,总缓解率100%、完全缓解率95%,83%实现PET-2阴性并可降阶治疗;3级及以上中性粒细胞减少83%、发热性中性粒细胞减少55%,但95%完成全部计划周期。

要点

  • 高危晚期cHL患者中BrECADD的1年PFS为96%、OS为100%。
  • 83%患者PET-2阴性,支持从6周期降阶至4周期治疗。
  • 3级及以上中性粒细胞减少83%、发热性中性粒细胞减少55%,但95%完成计划周期。

核心结论

  • 在包含高危患者的真实世界队列中,BrECADD显示出显著疗效和可耐受性,支持其可行性及减少化疗和放疗暴露的潜力。

研究设计与样本

  • 多中心回顾性研究,纳入19个癌症中心2023年7月至2025年10月接受BrECADD治疗的100例晚期经典型霍奇金淋巴瘤患者。
  • 主要终点为无进展生存期,次要终点包括总缓解率、PET-2阴性率、完全缓解、总生存期和毒性。

主要发现

  • 中位年龄30岁(范围18-65岁),80%为IV期,85%国际预后评分≥3。
  • 总缓解率100%,完全缓解率95%,83%实现PET-2阴性并支持从6周期降阶至4周期。
  • 中位随访13.7个月,估计1年无进展生存率96%、总生存率100%。
  • 仅4%需要放疗;3级及以上中性粒细胞减少83%,发热性中性粒细胞减少55%,95%完成全部计划周期;外周神经病变25%,多为1-2级。

临床怎么用

  • BrECADD可用于晚期经典型霍奇金淋巴瘤的真实世界治疗,包括高危患者。
  • PET-2阴性结果可支持将治疗从6周期降阶至4周期,减少化疗暴露。
  • 需关注3级及以上中性粒细胞减少和发热性中性粒细胞减少,但多数患者仍可完成全部计划周期。

局限性

  • 回顾性研究设计。
  • 中位随访仅13.7个月,生存数据不成熟。
  • 样本量100例,来自19个中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advanced-stage classical Hodgkin lymphoma (cHL) has been traditionally treated with effective chemotherapy regimens, albeit some associated with substantial toxicity. The recently introduced brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) regimen has proved more effective and less toxic than escalated BEACOPP (escBEACOPP: bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). Our retrospective multicentre study assessed outcomes of this treatment in the real-world setting. It incorporated 100 advanced-stage cHL patients receiving BrECADD at 19 cancer centres between July 2023 and October 2025. The primary end-point was progression-free survival (PFS); secondary end-points included overall response rate (ORR), positron emission tomography (PET)-2 negativity, complete response (CR), overall survival (OS) and toxicity. The median age was 30 (18-65) years; 80% had stage IV disease; 85% had an International Prognostic Score ≥3. ORR and CR were 100% and 95%, respectively; 83% achieved PET-2 negativity, enabling therapy de-escalation from six to four cycles. At a median follow-up of 13.7 months, estimated 1-year PFS and OS were 96% and 100% respectively. Only 4% required radiotherapy. Grade ≥3 neutropenia (83%) and febrile neutropenia (55%) were common; yet, 95% of patients completed all planned cycles. Peripheral neuropathy occurred in 25%, mostly grade 1-2. In this real-world cohort, including high-risk patients, BrECADD demonstrated remarkable efficacy and tolerability, supporting its feasibility and potential to reduce chemotherapy and radiotherapy exposure, while maintaining high treatment efficacy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Porges T, Levi T, Dann EJ, et al. Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study. Br J Haematol. 2026. PMID: 42448612. doi:10.1111/bjh.70682

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。